CPSF2 (cleavage and polyadenylation specific factor 2) is a core component of the cleavage and polyadenylation specificity factor (CPSF) complex that mediates pre-mRNA 3'-end processing. The complex recognizes the conserved AAUAAA signal sequence and coordinates with poly(A) polymerase and other factors to facilitate cleavage and poly(A) addition of mRNA transcripts 1. CPSF2 is also involved in histone pre-mRNA 3'-end processing. At the molecular level, CPSF2 interacts with multiple complex members including CPSF1, CPSF3, CPSF4, Symplekin, WDR33, and FIP1L1 1. Clinically, CPSF2 dysregulation associates with multiple diseases. Decreased CPSF2 expression in papillary thyroid cancer correlates with reduced disease-free survival, larger tumors, increased recurrence, and mortality 2. Loss of CPSF2 expression increases cellular invasion 1.8–3.2-fold and elevates cancer stem cell markers (CD44, CD133) 2. Negative CPSF2 protein expression independently predicts poorer outcome and lymph node/distant metastasis in thyroid carcinoma patients 3. Additionally, elevated serum anti-CPSF2 antibodies serve as predictive risk markers for acute ischemic stroke 4. CPSF2 emerges as a diagnostic and prognostic biomarker in hepatocellular carcinoma and dilated cardiomyopathy 5, 6, and represents a potential therapeutic target in influenza A virus infection 7.